<DOC>
	<DOC>NCT01030432</DOC>
	<brief_summary>The purpose of this study is to identify one or more doses of BMS-650032 that, when used in combination with pegylated-interferon alpha and ribavirin are safe and demonstrate sufficient activity against hepatitis C virus (Genotypes 1 and 4).</brief_summary>
	<brief_title>Study of BMS-650032 With Peginterferon Alfa-2a Plus Ribavirin</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Subjects chronically infected with HCV genotype 1 (Phase 2a and Phase 2b) Subjects chronically infected with HCV genotype 4 (Phase 2b only) HCV RNA viral load of ≥ 10*5* IU/mL at screening BMI of 18 35 kg/m² at screening Cirrhosis (Phase 2a only) Decompensated cirrhosis (Phase 2b) Coinfection with HBV or HIV Hepatocellular carcinoma Prior treatment with antiHCV drugs</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>